Log in

20 Stocks Analysts Can't Stop Upgrading in 2019

Posted on Sunday, December 15th, 2019 by MarketBeat Staff

As you know, a single upgrade from a broker probably won't be a major game changer for any single stock. But, what if there was a stock that had been upgraded by more than 10 different brokers during the last 90 days?

If ten different brokers have all upgraded a stock within the last few months and the price hasn't skyrocketed (at least, not yet), you would want to take a pretty hard look at it.

It turns out that there are actually 20 different companies that have been upgraded or had their price target increased at least ten times during the last ninety days by more than 10 different brokers. This slideshow lists those companies.

#1 - NVIDIA (NASDAQ:NVDA)

Number of Upgrades: 33 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.7
Ratings Breakdown: 27 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $218.39 (-2.5% Upside)

NVIDIA logoNVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the Graphics Processing Unit (GPU) and Tegra Processor segments. The GPU segment comprises of product brands which aims specialized markets including GeForce for gamers; Quadro for designers; Tesla and DGX for AI data scientists and big data researchers; and GRID for cloud-based visual computing users. The and Tegra Processor segment integrates an entire computer onto a single chip, and incorporates GPUs and multi-core CPUs to drive supercomputing for autonomous robots, drones, and cars, as well as for consoles and mobile gaming and entertainment devices. The company was founded by Jen-Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in January 1993 and is headquartered in Santa Clara, CA.

Recent Recommendations for NVIDIA:

  • NVIDIA Co. (NASDAQ: NVDA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. (12/13/2019)
  • NVIDIA Co. (NASDAQ: NVDA) had its "buy" rating re-affirmed by analysts at Citigroup Inc. They now have a $245.00 price target on the stock. (12/9/2019)
  • NVIDIA Co. (NASDAQ: NVDA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. (12/5/2019)
  • NVIDIA Co. (NASDAQ: NVDA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. (11/27/2019)
  • NVIDIA Co. (NASDAQ: NVDA) was upgraded by analysts at Morgan Stanley from an "equal" rating to a "weight" rating. They now have a $259.00 price target on the stock, up previously from $217.00. (11/25/2019)
  • NVIDIA Co. (NASDAQ: NVDA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $218.00 price target on the stock. (11/20/2019)
  • NVIDIA Co. (NASDAQ: NVDA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. (11/19/2019)
  • NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Piper Jaffray Companies from $200.00 to $230.00. They now have a "positive" rating on the stock. (11/15/2019)
  • NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at JPMorgan Chase & Co. from $200.00 to $237.00. They now have an "overweight" rating on the stock. (11/15/2019)
  • NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Barclays PLC from $170.00 to $225.00. They now have an "overweight" rating on the stock. (11/15/2019)

#2 - Apple (NASDAQ:AAPL)

Number of Upgrades: 28 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.5
Ratings Breakdown: 23 Buy Ratings, 11 Hold Ratings, 4 Sell Ratings.
Consensus Price Target: $251.70 (-8.5% Upside)

Apple logoApple Inc. designs, manufactures, and markets mobile communication and media devices, and personal computers. It also sells various related software, services, accessories, and third-party digital content and applications. The company offers iPhone, a line of smartphones; iPad, a line of multi-purpose tablets; and Mac, a line of desktop and portable personal computers, as well as iOS, macOS, watchOS, and tvOS operating systems. It also provides iTunes Store, an app store that allows customers to purchase and download, or stream music and TV shows; rent or purchase movies; and download free podcasts, as well as iCloud, a cloud service, which stores music, photos, contacts, calendars, mail, documents, and others. In addition, the company offers AppleCare support services; Apple Pay, a cashless payment service; Apple TV that connects to consumers' TVs and enables them to access digital content directly for streaming video, playing music and games, and viewing photos; and Apple Watch, a personal electronic device, as well as AirPods, Beats products, HomePod, iPod touch, and other Apple-branded and third-party accessories. The company serves consumers, and small and mid-sized businesses; and education, enterprise, and government customers worldwide. It sells and delivers digital content and applications through the iTunes Store, App Store, Mac App Store, TV App Store, Book Store, and Apple Music. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was founded in 1977 and is headquartered in Cupertino, California.

Recent Recommendations for Apple:

  • Apple Inc. (NASDAQ: AAPL) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $325.00 price target on the stock. (12/12/2019)
  • Apple Inc. (NASDAQ: AAPL) had its "outperform" rating re-affirmed by analysts at Evercore ISI. They now have a $305.00 price target on the stock, up previously from $275.00. (12/11/2019)
  • Apple Inc. (NASDAQ: AAPL) had its "hold" rating re-affirmed by analysts at Nomura. They now have a $225.00 price target on the stock. (12/10/2019)
  • Apple Inc. (NASDAQ: AAPL) was given a new $280.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock. (12/10/2019)
  • Apple Inc. (NASDAQ: AAPL) had its "sell" rating re-affirmed by analysts at Rosenblatt Securities. They now have a $150.00 price target on the stock. (12/9/2019)
  • Apple Inc. (NASDAQ: AAPL) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating and a $342.00 price target on the stock. (12/9/2019)
  • Apple Inc. (NASDAQ: AAPL) had its "hold" rating re-affirmed by analysts at Loop Capital. They now have a $265.00 price target on the stock. (12/6/2019)
  • Apple Inc. (NASDAQ: AAPL) had its price target raised by analysts at Citigroup Inc from $250.00 to $300.00. They now have a "buy" rating on the stock. (12/5/2019)
  • Apple Inc. (NASDAQ: AAPL) was downgraded by analysts at Maxim Group to a "sell" rating. They now have a $190.00 price target on the stock. (12/4/2019)
  • Apple Inc. (NASDAQ: AAPL) had its price target raised by analysts at JPMorgan Chase & Co. from $290.00 to $296.00. They now have an "overweight" rating on the stock. (12/2/2019)

#3 - Biogen (NASDAQ:BIIB)

Number of Upgrades: 22 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.2
Ratings Breakdown: 10 Buy Ratings, 21 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $291.23 (-1.9% Upside)

Biogen logoBiogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Recent Recommendations for Biogen:

  • Biogen Inc (NASDAQ: BIIB) was upgraded by analysts at Credit Suisse Group AG from an "underperform" rating to a "neutral" rating. They now have a $300.00 price target on the stock, up previously from $260.00. (12/13/2019)
  • Biogen Inc (NASDAQ: BIIB) had its "hold" rating re-affirmed by analysts at Raymond James. (12/6/2019)
  • Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $335.00 price target on the stock. (12/6/2019)
  • Biogen Inc (NASDAQ: BIIB) was downgraded by analysts at Robert W. Baird from a "neutral" rating to an "underperform" rating. They now have a $250.00 price target on the stock. (12/2/2019)
  • Biogen Inc (NASDAQ: BIIB) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. (11/23/2019)
  • Biogen Inc (NASDAQ: BIIB) had its "hold" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $267.00 price target on the stock. (11/18/2019)
  • Biogen Inc (NASDAQ: BIIB) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating and a $337.00 price target on the stock. (11/12/2019)
  • Biogen Inc (NASDAQ: BIIB) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. (11/8/2019)
  • Biogen Inc (NASDAQ: BIIB) was downgraded by analysts at Standpoint Research from a "buy" rating to a "hold" rating. (11/1/2019)
  • Biogen Inc (NASDAQ: BIIB) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. (11/1/2019)

#4 - Chipotle Mexican Grill (NYSE:CMG)

Number of Upgrades: 20 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.3
Ratings Breakdown: 14 Buy Ratings, 14 Hold Ratings, 5 Sell Ratings.
Consensus Price Target: $807.03 (-1.0% Upside)

Chipotle Mexican Grill logoChipotle Mexican Grill, Inc., together with its subsidiaries, operates Chipotle Mexican Grill restaurants. As of December 31, 2018, it operated 2,491 restaurants, including 2,452 Chipotle restaurants in the United States, 37 Chipotle restaurants internationally, and two non-Chipotle restaurants. The company was founded in 1993 and is headquartered in Newport Beach, California.

Recent Recommendations for Chipotle Mexican Grill:

  • Chipotle Mexican Grill, Inc. (NYSE: CMG) is now covered by analysts at Royal Bank of Canada. They set a "sector perform" rating and a $890.00 price target on the stock. (12/9/2019)
  • Chipotle Mexican Grill, Inc. (NYSE: CMG) was upgraded by analysts at Cowen Inc from a "market perform" rating to an "outperform" rating. They now have a $970.00 price target on the stock, up previously from $800.00. (11/26/2019)
  • Chipotle Mexican Grill, Inc. (NYSE: CMG) had its "buy" rating re-affirmed by analysts at Piper Jaffray Companies. They now have a $904.00 price target on the stock. (11/20/2019)
  • Chipotle Mexican Grill, Inc. (NYSE: CMG) had its "hold" rating re-affirmed by analysts at William Blair. (11/18/2019)
  • Chipotle Mexican Grill, Inc. (NYSE: CMG) had its price target raised by analysts at BMO Capital Markets from $640.00 to $650.00. They now have an "underperform" rating on the stock. (10/23/2019)
  • Chipotle Mexican Grill, Inc. (NYSE: CMG) had its "underperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $625.00 price target on the stock, up previously from $525.00. (10/23/2019)
  • Chipotle Mexican Grill, Inc. (NYSE: CMG) had its price target raised by analysts at UBS Group AG from $650.00 to $690.00. They now have a "sell" rating on the stock. (10/23/2019)
  • Chipotle Mexican Grill, Inc. (NYSE: CMG) had its price target raised by analysts at KeyCorp from $870.00 to $900.00. They now have an "overweight" rating on the stock. (10/23/2019)
  • Chipotle Mexican Grill, Inc. (NYSE: CMG) had its price target raised by analysts at Credit Suisse Group AG from $880.00 to $930.00. They now have an "outperform" rating on the stock. (10/23/2019)
  • Chipotle Mexican Grill, Inc. (NYSE: CMG) had its price target raised by analysts at JPMorgan Chase & Co. from $705.00 to $845.00. They now have a "neutral" rating on the stock. (10/23/2019)

#5 - Dicks Sporting Goods (NYSE:DKS)

Number of Upgrades: 19 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.4
Ratings Breakdown: 9 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $47.12 (-1.7% Upside)

Dicks Sporting Goods logoDick's Sporting Goods, Inc. operates as a sporting goods retailer primarily in the eastern United States. It provides hardlines, including sporting goods equipment, fitness equipment, golf equipment, and hunting and fishing gear products; apparel; and footwear and accessories. The company also owns and operates Golf Galaxy, Field & Stream, and other specialty concept stores; and e-commerce Websites, as well as Dick's Team Sports HQ, a youth sports digital platform that offers free league management services, mobile apps, free league management services, communications and live scorekeeping, custom uniforms and fan wear, and access to donations and sponsorships. As of May 3, 2019, it operated approximately 728 DICK'S sporting goods stores and 95 Golf Galaxy stores in 47 states. The company was formerly known as Dick's Clothing and Sporting Goods, Inc. and changed its name to Dick's Sporting Goods, Inc. in April 1999. Dick's Sporting Goods, Inc. was founded in 1948 and is headquartered in Coraopolis, Pennsylvania.

Recent Recommendations for Dicks Sporting Goods:

  • Dicks Sporting Goods Inc (NYSE: DKS) had its "market perform" rating re-affirmed by analysts at Royal Bank of Canada. (12/2/2019)
  • Dicks Sporting Goods Inc (NYSE: DKS) had its price target raised by analysts at Credit Suisse Group AG from $37.00 to $46.00. They now have a "neutral" rating on the stock. (11/29/2019)
  • Dicks Sporting Goods Inc (NYSE: DKS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $48.00 price target on the stock. (11/28/2019)
  • Dicks Sporting Goods Inc (NYSE: DKS) was upgraded by analysts at ValuEngine from a "strong sell" rating to a "sell" rating. (11/27/2019)
  • Dicks Sporting Goods Inc (NYSE: DKS) had its price target raised by analysts at Royal Bank of Canada from $40.00 to $47.00. They now have a "sector perform" rating on the stock. (11/27/2019)
  • Dicks Sporting Goods Inc (NYSE: DKS) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $56.00 price target on the stock, up previously from $45.00. (11/27/2019)
  • Dicks Sporting Goods Inc (NYSE: DKS) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $60.00 price target on the stock, up previously from $35.00. (11/27/2019)
  • Dicks Sporting Goods Inc (NYSE: DKS) had its price target raised by analysts at Nomura from $42.00 to $47.00. They now have a "neutral" rating on the stock. (11/27/2019)
  • Dicks Sporting Goods Inc (NYSE: DKS) had its price target raised by analysts at Morgan Stanley from $36.00 to $46.00. They now have an "equal weight" rating on the stock. (11/27/2019)
  • Dicks Sporting Goods Inc (NYSE: DKS) had its price target raised by analysts at Robert W. Baird from $36.00 to $51.00. They now have a "positive" rating on the stock. (11/26/2019)

#6 - Lululemon Athletica (NASDAQ:LULU)

Number of Upgrades: 17 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.6
Ratings Breakdown: 21 Buy Ratings, 13 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $230.17 (3.0% Upside)

Lululemon Athletica logolululemon athletica inc., together with its subsidiaries, designs, distributes, and retails athletic apparel and accessories for women, men, and female youth. It operates through two segments, Company-Operated Stores and Direct to Consumer. The company offers pants, shorts, tops, and jackets for healthy lifestyle and athletic activities, such as yoga, running, and training, as well as other sweaty pursuits; and athletic wear for female youth. It also provides fitness-related accessories, including bags, socks, underwear, yoga mats and equipment, and water bottles. The company sells its products through a chain of company-operated stores; outlets and warehouse sales; a network of wholesale accounts, such as yoga studios, health clubs, and fitness centers; temporary locations, including seasonal stores; license and supply arrangements; and showrooms, as well as directly to consumer through mobile apps, and lululemon.com e-commerce site. As of February 3, 2019, it operated 440 company-operated stores under the lululemon and ivivva brands in the United States, Canada, Australia, the United Kingdom, New Zealand, China, Singapore, France, Japan, Ireland, Sweden, South Korea, Germany, and Switzerland. lululemon athletica inc. was founded in 1998 and is based in Vancouver, Canada.

Recent Recommendations for Lululemon Athletica:

  • Lululemon Athletica inc. (NASDAQ: LULU) had its price target raised by analysts at Goldman Sachs Group Inc from $193.00 to $219.00. They now have a "neutral" rating on the stock. (12/13/2019)
  • Lululemon Athletica inc. (NASDAQ: LULU) had its "neutral" rating re-affirmed by analysts at DA Davidson. They now have a $220.00 price target on the stock. (12/13/2019)
  • Lululemon Athletica inc. (NASDAQ: LULU) had its price target raised by analysts at Morgan Stanley from $169.00 to $214.00. They now have an "equal weight" rating on the stock. (12/13/2019)
  • Lululemon Athletica inc. (NASDAQ: LULU) had its price target raised by analysts at Piper Jaffray Companies from $244.00 to $245.00. They now have an "overweight" rating on the stock. (12/12/2019)
  • Lululemon Athletica inc. (NASDAQ: LULU) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. (12/12/2019)
  • Lululemon Athletica inc. (NASDAQ: LULU) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $273.00 price target on the stock. (12/12/2019)
  • Lululemon Athletica inc. (NASDAQ: LULU) had its price target raised by analysts at MKM Partners from $255.00 to $258.00. They now have a "buy" rating on the stock. (12/12/2019)
  • Lululemon Athletica inc. (NASDAQ: LULU) had its price target raised by analysts at Credit Suisse Group AG from $235.00 to $250.00. (12/12/2019)
  • Lululemon Athletica inc. (NASDAQ: LULU) had its price target raised by analysts at Wells Fargo & Co from $230.00 to $260.00. They now have an "overweight" rating on the stock. (12/11/2019)
  • Lululemon Athletica inc. (NASDAQ: LULU) had its "buy" rating re-affirmed by analysts at Susquehanna Bancshares Inc. They now have a $260.00 price target on the stock. (12/11/2019)

#7 - Qorvo (NASDAQ:QRVO)

Number of Upgrades: 17 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.6
Ratings Breakdown: 10 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $93.29 (-17.7% Upside)

Qorvo logoQorvo, Inc. provides radio frequency (RF) solutions and technologies for mobile device, infrastructure, and defense and aerospace applications worldwide. It operates through Mobile Products (MP) and Infrastructure and Defense Products (IDP) segments. The MP segment offers cellular RF and WiFi solutions, bulk acoustic wave (BAW) and surface acoustic wave (SAW) filters, power amplifiers (PAs), low noise amplifiers (LNAs), switches, multi-band PAs and transmit modules, RF power management integrated circuits, diversity receive modules, antenna switch modules, antenna tuning and control solutions, modules incorporating PAs and duplexers, and modules incorporating switches, PAs, and duplexers. This segment supplies its solutions for use in mobile devices, including smartphones, notebook computers, wearables, tablets, and cellular-based applications for the Internet of Things (IoT). The IDP segment supplies RF solutions for communications and defense applications, such as high performance defense systems comprising radar, electronic warfare and communication systems, Wi-Fi customer premises equipment for home and work, high speed connectivity in long-term evolution and 5G base stations, cloud connectivity via data center communications and telecom transport, and automotive connectivity and other IoT, including smart home solutions. This segment provides gallium arsenide, gallium nitride power amplifiers, LNAs, switches, complementary metal oxide semiconductor system-on-a-chip solutions, premium BAW and SAW filter solutions, and various multichip and hybrid assemblies. The company sells its products directly to customers, as well as through a network of domestic and foreign sales representative firms and distributors to original equipment manufacturers and original design manufacturers. Qorvo, Inc. was founded in 1991 and is headquartered in Greensboro, North Carolina.

Recent Recommendations for Qorvo:

  • Qorvo Inc (NASDAQ: QRVO) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. (12/13/2019)
  • Qorvo Inc (NASDAQ: QRVO) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $120.00 price target on the stock, up previously from $95.00. (12/11/2019)
  • Qorvo Inc (NASDAQ: QRVO) was upgraded by analysts at Bank of America Corp from an "underperform" rating to a "buy" rating. (12/9/2019)
  • Qorvo Inc (NASDAQ: QRVO) was downgraded by analysts at Canaccord Genuity from a "buy" rating to a "hold" rating. They now have a $110.00 price target on the stock, up previously from $92.00. (11/13/2019)
  • Qorvo Inc (NASDAQ: QRVO) had its price target raised by analysts at Morgan Stanley from $77.00 to $104.00. They now have an "equal weight" rating on the stock. (11/11/2019)
  • Qorvo Inc (NASDAQ: QRVO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. (11/6/2019)
  • Qorvo Inc (NASDAQ: QRVO) had its price target raised by analysts at Morgan Stanley from $71.00 to $77.00. They now have a "weight" rating on the stock. (11/1/2019)
  • Qorvo Inc (NASDAQ: QRVO) had its price target raised by analysts at Bank of America Corp from $70.00 to $80.00. They now have an "underperform" rating on the stock. (11/1/2019)
  • Qorvo Inc (NASDAQ: QRVO) had its price target raised by analysts at BMO Capital Markets to $85.00. They now have a "positive" rating on the stock. (11/1/2019)
  • Qorvo Inc (NASDAQ: QRVO) had its price target raised by analysts at Piper Jaffray Companies from $85.00 to $95.00. They now have an "overweight" rating on the stock. (11/1/2019)

#8 - Seattle Genetics (NASDAQ:SGEN)

Number of Upgrades: 17 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.7
Ratings Breakdown: 13 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $111.47 (-2.1% Upside)

Seattle Genetics logoSeattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Recent Recommendations for Seattle Genetics:

  • Seattle Genetics, Inc. (NASDAQ: SGEN) had its "buy" rating re-affirmed by analysts at William Blair. (12/13/2019)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $140.00 price target on the stock. (12/13/2019)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $110.00 to $124.00. They now have an "outperform" rating on the stock. (12/12/2019)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock. (12/12/2019)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $123.00 price target on the stock. (12/10/2019)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. (12/10/2019)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) is now covered by analysts at Bank of America Corp. They set a "neutral" rating and a $125.00 price target on the stock. (12/3/2019)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. (12/3/2019)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. (11/16/2019)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. (11/6/2019)

#9 - Lam Research (NASDAQ:LRCX)

Number of Upgrades: 17 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.4
Ratings Breakdown: 9 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $259.76 (-7.9% Upside)

Lam Research logoLam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits worldwide. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition product for copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatment; SPEED gapfill high-density plasma chemical vapor deposition (CVD) products; Striker single-wafer atomic layer deposition (ALD) products; and VECTOR plasma-enhanced CVD ALD products. It also provides Flex for dielectric etch applications; Kiyo for conductor etch applications; Syndion for through-silicon via etch applications; and Versys metal products for metal etch processes. In addition, the company offers Coronus bevel clean products to enhance die yield; and Da Vinci, DV-Prime, EOS, SP to address a range of wafer cleaning. Further, it provides Metryx mass metrology systems for high aspect ratio etch, conformal and ALD/sidewall deposition, horizontal processing, film density monitoring, carbon mask open, and wafer cleaning/polymer removal applications; and legacy products. Lam Research Corporation was founded in 1980 and is headquartered in Fremont, California.

Recent Recommendations for Lam Research:

  • Lam Research Co. (NASDAQ: LRCX) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. (12/13/2019)
  • Lam Research Co. (NASDAQ: LRCX) was downgraded by analysts at UBS Group AG from a "neutral" rating to a "sell" rating. (11/27/2019)
  • Lam Research Co. (NASDAQ: LRCX) had its "overweight" rating re-affirmed by analysts at KeyCorp. They now have a $313.00 price target on the stock, up previously from $261.00. (11/25/2019)
  • Lam Research Co. (NASDAQ: LRCX) was downgraded by analysts at UBS Group AG from a "neutral" rating to a "sell" rating. They now have a $240.00 price target on the stock. (11/21/2019)
  • Lam Research Co. (NASDAQ: LRCX) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. (11/21/2019)
  • Lam Research Co. (NASDAQ: LRCX) had its price target raised by analysts at Stifel Nicolaus from $284.00 to $319.00. They now have a "buy" rating on the stock. (11/12/2019)
  • Lam Research Co. (NASDAQ: LRCX) had its price target raised by analysts at Citigroup Inc from $282.00 to $330.00. They now have a "buy" rating on the stock. (11/5/2019)
  • Lam Research Co. (NASDAQ: LRCX) had its price target lowered by analysts at KeyCorp from $261.00 to $252.00. They now have an "overweight" rating on the stock. (10/24/2019)
  • Lam Research Co. (NASDAQ: LRCX) had its price target raised by analysts at Royal Bank of Canada from $230.00 to $273.00. They now have an "outperform" rating on the stock. (10/24/2019)
  • Lam Research Co. (NASDAQ: LRCX) had its "outperform" rating re-affirmed by analysts at Credit Suisse Group AG. They now have a $300.00 price target on the stock, up previously from $278.00. (10/24/2019)

#10 - Edwards Lifesciences (NYSE:EW)

Number of Upgrades: 16 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.6
Ratings Breakdown: 12 Buy Ratings, 4 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $238.06 (2.3% Upside)

Edwards Lifesciences logoEdwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; Acumen Hypotension Prediction Index, an advanced algorithm that indicates the likelihood of a patient developing hypotension; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

Recent Recommendations for Edwards Lifesciences:

  • Edwards Lifesciences Corp (NYSE: EW) had its price target raised by analysts at Piper Jaffray Companies from $255.00 to $262.00. They now have an "overweight" rating on the stock. (12/9/2019)
  • Edwards Lifesciences Corp (NYSE: EW) had its price target raised by analysts at Morgan Stanley from $248.00 to $270.00. They now have an "overweight" rating on the stock. (12/6/2019)
  • Edwards Lifesciences Corp (NYSE: EW) had its price target raised by analysts at Wells Fargo & Co from $262.00 to $270.00. They now have an "outperform" rating on the stock. (12/6/2019)
  • Edwards Lifesciences Corp (NYSE: EW) had its price target raised by analysts at Credit Suisse Group AG from $269.00 to $275.00. They now have an "outperform" rating on the stock. (12/6/2019)
  • Edwards Lifesciences Corp (NYSE: EW) had its price target raised by analysts at Raymond James from $255.00 to $263.00. They now have an "outperform" rating on the stock. (12/6/2019)
  • Edwards Lifesciences Corp (NYSE: EW) had its price target raised by analysts at UBS Group AG from $250.00 to $255.00. They now have a "neutral" rating on the stock. (12/6/2019)
  • Edwards Lifesciences Corp (NYSE: EW) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $260.00 price target on the stock. (12/6/2019)
  • Edwards Lifesciences Corp (NYSE: EW) had its price target raised by analysts at Jefferies Financial Group Inc from $255.00 to $285.00. They now have a "buy" rating on the stock. (12/3/2019)
  • Edwards Lifesciences Corp (NYSE: EW) had its price target raised by analysts at Cowen Inc from $250.00 to $265.00. They now have a "positive" rating on the stock. (10/24/2019)
  • Edwards Lifesciences Corp (NYSE: EW) had its price target raised by analysts at Piper Jaffray Companies from $240.00 to $255.00. They now have an "overweight" rating on the stock. (10/24/2019)

#11 - Cloudera (NYSE:CLDR)

Number of Upgrades: 16 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.3
Ratings Breakdown: 6 Buy Ratings, 11 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $12.28 (11.2% Upside)

Cloudera logoCloudera, Inc. provides a suite of data analytics and management products in the United States, Europe, and Asia. The company operates through two segments, Subscription and Services. It offers Cloudera Enterprise Data Hub that allows companies to execute various analytic functions against a shared set of governed and secures data in public and private clouds, and data centers; Cloudera Data Warehouse, a hybrid cloud solution for self-service analytics; Cloudera Data Science and Engineering enables users to streamline, simplify, and scale big data processing; and Cloudera Operational DB that enables stream processing and real-time analytics on continuously changing data. The company also provides Cloudera DataFlow, a data platform that collects, curates and analyzes data; Hortonworks Data Platform, a data management platform that helps organizations to securely store, process, and analyze various data assets; Cloudera Data Science Workbench that enables self-service data science for the enterprise; Cloudera Altus, a platform-as-a-service offering; and Cloudera Fast Forward Labs, which delivers applied research in machine learning and artificial intelligence to its customers. In addition, it offers Cloudera SDX, a solution that enables common security, governance, and metadata management for multiple analytics functions; Cloudera Workload XM, an analytic workload experience management cloud service; Hortonworks DataPlane Service, a data fabric that enables businesses to discover, manage, and govern their data; and Hortonworks Cybersecurity Platform, which offers a single, comprehensive view of business risk through a security lens. Further, the company provides consulting, professional, and education services. It serves corporate enterprises and public sector organizations primarily through its direct sales force. The company has strategic partnerships with Intel Corporation. Cloudera, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Recent Recommendations for Cloudera:

  • Cloudera Inc (NYSE: CLDR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. They now have a $12.00 price target on the stock. (12/10/2019)
  • Cloudera Inc (NYSE: CLDR) had its price target raised by analysts at Citigroup Inc from $8.00 to $10.00. They now have a "neutral" rating on the stock. (12/9/2019)
  • Cloudera Inc (NYSE: CLDR) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. (12/9/2019)
  • Cloudera Inc (NYSE: CLDR) had its price target raised by analysts at Nomura from $10.00 to $11.00. They now have a "buy" rating on the stock. (12/9/2019)
  • Cloudera Inc (NYSE: CLDR) had its "hold" rating re-affirmed by analysts at Barclays PLC. They now have a $11.00 price target on the stock. (12/8/2019)
  • Cloudera Inc (NYSE: CLDR) had its price target raised by analysts at Bank of America Corp from $7.00 to $8.00. They now have an "underperform" rating on the stock. (12/6/2019)
  • Cloudera Inc (NYSE: CLDR) had its price target raised by analysts at JMP Securities from $12.00 to $15.00. They now have an "outperform" rating on the stock. (12/6/2019)
  • Cloudera Inc (NYSE: CLDR) had its price target raised by analysts at JPMorgan Chase & Co. from $9.00 to $11.00. They now have a "neutral" rating on the stock. (12/6/2019)
  • Cloudera Inc (NYSE: CLDR) had its price target raised by analysts at Wedbush from $8.50 to $11.00. They now have a "neutral" rating on the stock. (12/6/2019)
  • Cloudera Inc (NYSE: CLDR) had its "hold" rating re-affirmed by analysts at Wells Fargo & Co. (12/6/2019)

#12 - Intel (NASDAQ:INTC)

Number of Upgrades: 16 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.2
Ratings Breakdown: 17 Buy Ratings, 12 Hold Ratings, 8 Sell Ratings.
Consensus Price Target: $56.34 (-2.5% Upside)

Intel logoIntel Corporation offers computing, networking, data storage, and communication solutions worldwide. It operates through Client Computing Group, Data Center Group, Internet of Things Group, Non-Volatile Memory Solutions Group, Programmable Solutions Group, and All Other segments. The company offers microprocessors, and system-on-chip and multichip packaging products. It also provides NAND flash memory products primarily used in solid-state drives; and programmable semiconductors and related products for communications, data center, industrial, and military markets. In addition, the company develops computer vision and machine learning, data analysis, localization, and mapping for advanced driver assistance systems and autonomous driving. Its platforms are used in notebooks, systems, and desktops; cloud, enterprise, and communication infrastructure market segments; and retail, automotive, industrial, and various other embedded applications. It serves original equipment manufacturers, original design manufacturers, industrial and communication equipment manufacturers, and cloud service providers. Intel Corporation has a collaboration with Telefonaktiebolaget LM Ericsson (publ) to develop software defined infrastructure for network functions virtualization, distributed cloud, and 5G applications. The company was founded in 1968 and is based in Santa Clara, California.

Recent Recommendations for Intel:

  • Intel Co. (NASDAQ: INTC) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. (12/13/2019)
  • Intel Co. (NASDAQ: INTC) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. (12/7/2019)
  • Intel Co. (NASDAQ: INTC) had its price target raised by analysts at Bank of America Corp from $65.00 to $70.00. They now have a "positive" rating on the stock. (12/2/2019)
  • Intel Co. (NASDAQ: INTC) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. (11/30/2019)
  • Intel Co. (NASDAQ: INTC) had its price target raised by analysts at Mizuho from $60.00 to $64.00. They now have a "buy" rating on the stock. (11/20/2019)
  • Intel Co. (NASDAQ: INTC) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. (11/9/2019)
  • Intel Co. (NASDAQ: INTC) had its "sell" rating re-affirmed by analysts at Rosenblatt Securities. (11/6/2019)
  • Intel Co. (NASDAQ: INTC) had its "buy" rating re-affirmed by analysts at Northland Securities. They now have a $69.00 price target on the stock. (11/5/2019)
  • Intel Co. (NASDAQ: INTC) was given a new $65.00 price target on by analysts at Bank of America Corp. They now have a "buy" rating on the stock. (11/1/2019)
  • Intel Co. (NASDAQ: INTC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $59.00 price target on the stock. (10/28/2019)

#13 - Lowe's Companies (NYSE:LOW)

Number of Upgrades: 16 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.8
Ratings Breakdown: 21 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $129.48 (9.3% Upside)

LoweLowe's Companies, Inc., together with its subsidiaries, operates as a home improvement retailer in the United States, Canada, and Mexico. The company offers a line of products for construction, maintenance, repair, remodeling, and decorating. It provides home improvement products in various categories, such as lumber and building materials, appliances, seasonal and outdoor living, tools and hardware, fashion fixtures, rough plumbing and electrical, paint, millwork, lawn and garden, flooring, and kitchens. It also offers installation services through independent contractors in various product categories; extended protection plans; and in-warranty and out-of-warranty repair services. The company sells its national brand-name merchandise and private branded products to homeowners, renters, and professional customers. As of February 1, 2019, it operated 2,015 home improvement and hardware stores. The company also sells its products through online sites comprising Lowes.com and Lowesforpros.com; and through mobile applications. Lowe's Companies, Inc. was founded in 1946 and is based in Mooresville, North Carolina.

Recent Recommendations for Lowe's Companies:

  • Lowe's Companies, Inc. (NYSE: LOW) had its price target raised by analysts at Goldman Sachs Group Inc from $123.00 to $135.00. (11/27/2019)
  • Lowe's Companies, Inc. (NYSE: LOW) had its "buy" rating re-affirmed by analysts at Barclays PLC. They now have a $130.00 price target on the stock. (11/22/2019)
  • Lowe's Companies, Inc. (NYSE: LOW) had its price target raised by analysts at SunTrust Banks, Inc. from $120.00 to $135.00. They now have a "buy" rating on the stock. (11/22/2019)
  • Lowe's Companies, Inc. (NYSE: LOW) had its price target raised by analysts at Telsey Advisory Group from $120.00 to $133.00. They now have an "outperform" rating on the stock. (11/21/2019)
  • Lowe's Companies, Inc. (NYSE: LOW) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $135.00 price target on the stock. (11/21/2019)
  • Lowe's Companies, Inc. (NYSE: LOW) had its price target raised by analysts at Nomura from $132.00 to $137.00. They now have a "buy" rating on the stock. (11/21/2019)
  • Lowe's Companies, Inc. (NYSE: LOW) had its price target raised by analysts at Guggenheim from $130.00 to $135.00. They now have a "buy" rating on the stock. (11/21/2019)
  • Lowe's Companies, Inc. (NYSE: LOW) had its price target raised by analysts at Goldman Sachs Group Inc from $123.00 to $135.00. They now have a "buy" rating on the stock. (11/21/2019)
  • Lowe's Companies, Inc. (NYSE: LOW) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. (11/20/2019)
  • Lowe's Companies, Inc. (NYSE: LOW) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $135.00 price target on the stock. (11/20/2019)

#14 - Nike (NYSE:NKE)

Number of Upgrades: 16 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.6
Ratings Breakdown: 23 Buy Ratings, 8 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $98.86 (1.1% Upside)

Nike logoNIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells athletic footwear, apparel, equipment, and accessories worldwide. The company offers NIKE brand products in six categories: running, NIKE basketball, the Jordan brand, football, training, and sportswear. It also markets products designed for kids, as well as for other athletic and recreational uses, such as American football, baseball, cricket, lacrosse, skateboarding, tennis, volleyball, wrestling, walking, and outdoor activities; and apparel with licensed college and professional team and league logos, as well as sells sports apparel. In addition, the company sells a line of performance equipment and accessories, including bags, socks, sport balls, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment under the NIKE brand for sports activities; various plastic products to other manufacturers; athletic and casual footwear, apparel, and accessories under the Jumpman trademark; casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks; and action sports and youth lifestyle apparel and accessories under the Hurley trademark. Further, it licenses agreements that permit unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. NIKE, Inc. sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. The company was formerly known as Blue Ribbon Sports, Inc. and changed its name to NIKE, Inc. in 1971. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.

Recent Recommendations for Nike:

  • Nike Inc (NYSE: NKE) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $110.00 price target on the stock. (12/13/2019)
  • Nike Inc (NYSE: NKE) was given a new $112.00 price target on by analysts at Credit Suisse Group AG. They now have a "buy" rating on the stock. (12/13/2019)
  • Nike Inc (NYSE: NKE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $110.00 price target on the stock, up previously from $100.00. (12/11/2019)
  • Nike Inc (NYSE: NKE) had its "neutral" rating re-affirmed by analysts at Bank of America Corp. They now have a $105.00 price target on the stock, up previously from $98.00. (12/10/2019)
  • Nike Inc (NYSE: NKE) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $97.00 price target on the stock. (12/10/2019)
  • Nike Inc (NYSE: NKE) had its "buy" rating re-affirmed by analysts at Morgan Stanley. They now have a $118.00 price target on the stock. (12/10/2019)
  • Nike Inc (NYSE: NKE) was upgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "buy" rating. They now have a $112.00 price target on the stock. (12/5/2019)
  • Nike Inc (NYSE: NKE) had its price target raised by analysts at Morgan Stanley from $108.00 to $118.00. They now have an "overweight" rating on the stock. (12/2/2019)
  • Nike Inc (NYSE: NKE) had its "buy" rating re-affirmed by analysts at Guggenheim. (11/13/2019)
  • Nike Inc (NYSE: NKE) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $111.00 price target on the stock. (11/12/2019)

#15 - Adobe (NASDAQ:ADBE)

Number of Upgrades: 16 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.7
Ratings Breakdown: 17 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $321.44 (1.1% Upside)

Adobe logoAdobe Inc. operates as a diversified software company worldwide. Its Digital Media segment provides tools and solutions that enable individuals, small and medium businesses, and enterprises to create, publish, promote, and monetize their digital content. Its flagship product is Creative Cloud, a subscription service that allows customer to download and access the latest versions of its creative products. This segment serves traditional content creators, Web application developers, and digital media professionals, as well as their management in marketing departments and agencies, companies, and publishers. The company's Digital Experience segment offers solutions for how digital advertising and marketing are created, managed, executed, measured, and optimized. This segment provides analytics, social marketing, targeting, media optimization, digital experience management, cross-channel campaign management, marketing automation, audience management, and video delivery and monetization solutions to digital marketers, advertisers, publishers, merchandisers, Web analysts, chief marketing officers, chief information officers, and chief revenue officers. Its Publishing segment offers products and services, such as e-learning solutions, technical document publishing, Web application development, and high-end printing, as well as publishing needs of technical and business, and original equipment manufacturers (OEMs) printing businesses. The company offers its products and services directly to enterprise customers through its sales force, as well as to end-users through app stores and through its Website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and OEMs. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. The company was founded in 1982 and is headquartered in San Jose, California.

Recent Recommendations for Adobe:

  • Adobe Inc (NASDAQ: ADBE) had its price target raised by analysts at Barclays PLC from $330.00 to $350.00. They now have an "overweight" rating on the stock. (12/13/2019)
  • Adobe Inc (NASDAQ: ADBE) had its price target raised by analysts at Piper Jaffray Companies from $339.00 to $360.00. They now have an "overweight" rating on the stock. (12/13/2019)
  • Adobe Inc (NASDAQ: ADBE) had its "outperform" rating re-affirmed by analysts at Credit Suisse Group AG. They now have a $350.00 price target on the stock, up previously from $325.00. (12/13/2019)
  • Adobe Inc (NASDAQ: ADBE) had its price target raised by analysts at Wedbush from $290.00 to $315.00. They now have a "neutral" rating on the stock. (12/13/2019)
  • Adobe Inc (NASDAQ: ADBE) had its price target raised by analysts at Wells Fargo & Co from $285.00 to $315.00. They now have an "equal weight" rating on the stock. (12/13/2019)
  • Adobe Inc (NASDAQ: ADBE) had its price target raised by analysts at Canaccord Genuity from $320.00 to $350.00. They now have a "buy" rating on the stock. (12/13/2019)
  • Adobe Inc (NASDAQ: ADBE) had its price target raised by analysts at Nomura from $310.00 to $318.00. They now have a "buy" rating on the stock. (12/13/2019)
  • Adobe Inc (NASDAQ: ADBE) had its price target raised by analysts at Griffin Securities from $330.00 to $334.00. They now have a "buy" rating on the stock. (12/13/2019)
  • Adobe Inc (NASDAQ: ADBE) had its price target raised by analysts at Stifel Nicolaus from $325.00 to $350.00. They now have a "buy" rating on the stock. (12/13/2019)
  • Adobe Inc (NASDAQ: ADBE) had its "buy" rating re-affirmed by analysts at UBS Group AG. They now have a $360.00 price target on the stock. (12/13/2019)

#16 - Skyworks Solutions (NASDAQ:SWKS)

Number of Upgrades: 15 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.5
Ratings Breakdown: 13 Buy Ratings, 14 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $98.07 (-12.3% Upside)

Skyworks Solutions logoSkyworks Solutions, Inc., together with its subsidiaries, designs, develops, manufactures, and markets proprietary semiconductor products, including intellectual property worldwide. Its product portfolio includes amplifiers, antenna tuners, attenuators, circulators/isolators, DC/DC converters, demodulators, detectors, diodes, directional couplers, diversity receive modules, filters, front-end modules, hybrids, LED drivers, low noise amplifiers, mixers, modulators, optocouplers/optoisolators, phase locked loops, phase shifters, power dividers/combiners, receivers, switches, synthesizers, technical ceramics, voltage controlled oscillators/synthesizers, and voltage regulators. The company provides its products for use in the aerospace, automotive, broadband, cellular infrastructure, connected home, industrial, medical, military, smartphone, tablet, and wearable markets. It sells its products through direct sales force, electronic component distributors, and independent sales representatives. Skyworks Solutions, Inc. has a collaboration agreement with MediaTek Incorporated to deliver standards-based 5G solution. The company was founded in 1962 and is headquartered in Woburn, Massachusetts.

Recent Recommendations for Skyworks Solutions:

  • Skyworks Solutions Inc (NASDAQ: SWKS) was upgraded by analysts at Bank of America Corp from an "underperform" rating to a "buy" rating. They now have a $122.00 price target on the stock. (12/9/2019)
  • Skyworks Solutions Inc (NASDAQ: SWKS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. (12/7/2019)
  • Skyworks Solutions Inc (NASDAQ: SWKS) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. (11/19/2019)
  • Skyworks Solutions Inc (NASDAQ: SWKS) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $110.00 price target on the stock, up previously from $90.00. (11/13/2019)
  • Skyworks Solutions Inc (NASDAQ: SWKS) had its "outperform" rating re-affirmed by analysts at Cowen Inc. They now have a $105.00 price target on the stock, up previously from $95.00. (11/13/2019)
  • Skyworks Solutions Inc (NASDAQ: SWKS) had its price target raised by analysts at Mizuho from $76.00 to $90.00. They now have a "neutral" rating on the stock. (11/13/2019)
  • Skyworks Solutions Inc (NASDAQ: SWKS) was downgraded by analysts at Canaccord Genuity from a "buy" rating to a "hold" rating. They now have a $102.00 price target on the stock, up previously from $82.00. (11/13/2019)
  • Skyworks Solutions Inc (NASDAQ: SWKS) had its price target raised by analysts at B. Riley from $105.00 to $115.00. They now have a "buy" rating on the stock. (11/13/2019)
  • Skyworks Solutions Inc (NASDAQ: SWKS) had its price target raised by analysts at Benchmark Co. from $94.00 to $110.00. They now have a "buy" rating on the stock. (11/13/2019)
  • Skyworks Solutions Inc (NASDAQ: SWKS) had its price target raised by analysts at Loop Capital to $120.00. They now have a "buy" rating on the stock. (11/13/2019)

#17 - TJX Companies (NYSE:TJX)

Number of Upgrades: 14 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.8
Ratings Breakdown: 15 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $65.39 (8.3% Upside)

TJX Companies logoThe TJX Companies, Inc. operates as an off-price apparel and home fashions retailer. It operates through four segments: Marmaxx, HomeGoods, TJX Canada, and TJX International. The company sells family apparel, including footwear and accessories; home fashions, such as home basics, furniture, rugs, lighting products, giftware, soft home products, decorative accessories, tabletop, and cookware, as well as expanded pet, kids, and gourmet food departments; jewelry and accessories; footwear; and other merchandise. It operates stores under the T.J. Maxx, Marshalls, HomeGoods, Winners, HomeSense, T.K. Maxx, and Sierra Trading Post names, as well as operates e-commerce sites tjmaxx.com, tkmaxx.com, and sierratradingpost.com. The company operates a total of approximately 4,300 stores in 9 countries, which included the United States, Canada, the United Kingdom, Ireland, Germany, Poland, Austria, the Netherlands, and Australia. The TJX Companies, Inc. was founded in 1956 and is headquartered in Framingham, Massachusetts.

Recent Recommendations for TJX Companies:

  • TJX Companies Inc (NYSE: TJX) had its price target raised by analysts at Cowen Inc from $64.00 to $71.00. They now have an "outperform" rating on the stock. (12/9/2019)
  • TJX Companies Inc (NYSE: TJX) had its "hold" rating re-affirmed by analysts at Wells Fargo & Co. (12/9/2019)
  • TJX Companies Inc (NYSE: TJX) had its "buy" rating re-affirmed by analysts at Morgan Stanley. They now have a $62.00 price target on the stock. (12/9/2019)
  • TJX Companies Inc (NYSE: TJX) had its price target raised by analysts at Robert W. Baird from $63.00 to $69.00. They now have a "positive" rating on the stock. (12/5/2019)
  • TJX Companies Inc (NYSE: TJX) had its "buy" rating re-affirmed by analysts at Evercore ISI. They now have a $70.00 price target on the stock. (11/21/2019)
  • TJX Companies Inc (NYSE: TJX) had its "positive" rating re-affirmed by analysts at DA Davidson. They now have a $70.00 price target on the stock, up previously from $65.00. (11/20/2019)
  • TJX Companies Inc (NYSE: TJX) had its price target raised by analysts at Telsey Advisory Group from $62.00 to $68.00. They now have an "outperform" rating on the stock. (11/20/2019)
  • TJX Companies Inc (NYSE: TJX) had its price target raised by analysts at MKM Partners to $70.00. They now have a "buy" rating on the stock. (11/20/2019)
  • TJX Companies Inc (NYSE: TJX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock. (11/20/2019)
  • TJX Companies Inc (NYSE: TJX) had its price target raised by analysts at Loop Capital to $69.00. They now have a "buy" rating on the stock. (11/20/2019)

#18 - Sherwin-Williams (NYSE:SHW)

Number of Upgrades: 14 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.6
Ratings Breakdown: 12 Buy Ratings, 10 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $579.09 (1.2% Upside)

Sherwin-Williams logoThe Sherwin-Williams Company develops, manufactures, distributes, and sells paints, coatings, and related products to professional, industrial, commercial, and retail customers. It operates in three segments: The Americas Group, Consumer Brands Group, and Performance Coatings Group. The Americas Group segment offers architectural paints and coatings, and protective and marine products, as well as OEM product finishes and related products for architectural and industrial paint contractors and do-it-yourself homeowners. The Consumer Brands Group segment provides branded and private-label architectural paints, stains, varnishes, industrial products, wood finishes products, wood preservatives, applicators, corrosion inhibitors, aerosols, caulks, and adhesives to retailers and distributors. The Performance Coatings Group segment develops and sells industrial coatings for wood finishing and general industrial applications, automotive refinish products, protective and marine coatings, coil coatings, packaging coatings, and performance-based resins and colorants. It serves retailers, dealers, jobbers, licensees, and other third-party distributors through its branches and direct sales staff, as well as through outside sales representatives. The company has operations primarily in North and South America, the Caribbean, Europe, Asia, and Australia. As of February 19, 2019, it operated approximately 4,900 company-operated stores and facilities. The company was founded in 1866 and is headquartered in Cleveland, Ohio.

Recent Recommendations for Sherwin-Williams:

  • Sherwin-Williams Co (NYSE: SHW) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. (11/27/2019)
  • Sherwin-Williams Co (NYSE: SHW) was downgraded by analysts at Edward Jones from a "buy" rating to a "hold" rating. (11/19/2019)
  • Sherwin-Williams Co (NYSE: SHW) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. They now have a $578.00 price target on the stock, down previously from $616.00. (11/18/2019)
  • Sherwin-Williams Co (NYSE: SHW) is now covered by analysts at Berenberg Bank. They set a "hold" rating and a $600.00 price target on the stock. (11/6/2019)
  • Sherwin-Williams Co (NYSE: SHW) was given a new $631.00 price target on by analysts at Royal Bank of Canada. They now have a "buy" rating on the stock. (10/25/2019)
  • Sherwin-Williams Co (NYSE: SHW) had its price target raised by analysts at Robert W. Baird from $600.00 to $650.00. They now have a "top pick" rating on the stock. (10/23/2019)
  • Sherwin-Williams Co (NYSE: SHW) had its price target raised by analysts at Morgan Stanley from $600.00 to $650.00. They now have an "overweight" rating on the stock. (10/23/2019)
  • Sherwin-Williams Co (NYSE: SHW) had its price target raised by analysts at Credit Suisse Group AG from $587.00 to $610.00. They now have an "outperform" rating on the stock. (10/23/2019)
  • Sherwin-Williams Co (NYSE: SHW) had its price target raised by analysts at Wells Fargo & Co from $565.00 to $650.00. They now have an "outperform" rating on the stock. (10/23/2019)
  • Sherwin-Williams Co (NYSE: SHW) had its price target raised by analysts at UBS Group AG from $555.00 to $570.00. They now have a "neutral" rating on the stock. (10/23/2019)

#19 - easyJet (LON:EZJ)

Number of Upgrades: 14 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.0
Ratings Breakdown: 4 Buy Ratings, 13 Hold Ratings, 4 Sell Ratings.
Consensus Price Target: GBX 1,286.48 (-12.5% Upside)

easyJet logoeasyJet plc, together with its subsidiaries, operates as an airline carrier primarily in Europe. As of September 30, 2018, the company operated 979 routes and a fleet of 315 aircraft. It also engages in the trading and leasing of aircraft; and the provision of graphic design services. easyJet plc was founded in 1995 and is based in Luton, the United Kingdom.

Recent Recommendations for easyJet:

  • easyJet plc (LON: EZJ) was given a new GBX 1,500 price target on by analysts at HSBC Holdings plc. They now have a "buy" rating on the stock. (12/13/2019)
  • easyJet plc (LON: EZJ) had its price target raised by analysts at Deutsche Bank AG from GBX 1,150 to GBX 1,540. They now have a "hold" rating on the stock. (12/12/2019)
  • easyJet plc (LON: EZJ) had its price target raised by analysts at Main First Bank AG from GBX 950 to GBX 1,400. They now have a "neutral" rating on the stock. (12/6/2019)
  • easyJet plc (LON: EZJ) had its price target raised by analysts at Societe Generale from GBX 1,000 to GBX 1,280. They now have a "sell" rating on the stock. (11/29/2019)
  • easyJet plc (LON: EZJ) had its "outperform" rating re-affirmed by analysts at Credit Suisse Group AG. They now have a GBX 1,546 price target on the stock, up previously from GBX 1,431. (11/29/2019)
  • easyJet plc (LON: EZJ) was given a new GBX 1,100 price target on by analysts at UBS Group AG. They now have a "neutral" rating on the stock. (11/29/2019)
  • easyJet plc (LON: EZJ) had its price target raised by analysts at Citigroup Inc from GBX 1,200 to GBX 1,500. They now have a "buy" rating on the stock. (11/29/2019)
  • easyJet plc (LON: EZJ) was downgraded by analysts at Berenberg Bank to a "hold" rating. They now have a GBX 1,410 price target on the stock, up previously from GBX 1,260. (11/26/2019)
  • easyJet plc (LON: EZJ) had its "sell" rating re-affirmed by analysts at Kepler Capital Markets. They now have a GBX 930 price target on the stock. (11/25/2019)
  • easyJet plc (LON: EZJ) had its price target raised by analysts at Commerzbank AG from GBX 1,150 to GBX 1,450. They now have a "hold" rating on the stock. (11/21/2019)

#20 - Reata Pharmaceuticals (NASDAQ:RETA)

Number of Upgrades: 14 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.9
Ratings Breakdown: 7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $255.63 (23.6% Upside)

Reata Pharmaceuticals logoReata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.

Recent Recommendations for Reata Pharmaceuticals:

  • Reata Pharmaceuticals Inc (NASDAQ: RETA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. (12/11/2019)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. (12/3/2019)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. (11/27/2019)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) had its price target raised by analysts at Cantor Fitzgerald from $250.00 to $314.00. (11/27/2019)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $314.00 price target on the stock, up previously from $250.00. (11/20/2019)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $305.00 price target on the stock, up previously from $210.00. (11/14/2019)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) was downgraded by analysts at National Securities from a "buy" rating to a "neutral" rating. (11/13/2019)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) had its price target raised by analysts at Robert W. Baird from $162.00 to $245.00. They now have a "positive" rating on the stock. (11/12/2019)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) had its price target raised by analysts at Citigroup Inc from $241.00 to $328.00. They now have a "buy" rating on the stock. (11/12/2019)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) had its price target raised by analysts at Cantor Fitzgerald from $180.00 to $250.00. They now have an "overweight" rating on the stock. (11/4/2019)





More on MarketBeat
Best Growth Stocks - Best Stocks to Buy NowBest Growth Stocks - Best Stocks to Buy Now
7 Stocks That Insiders are Buying Now7 Stocks That Insiders are Buying Now
15 Stocks that Insiders Love15 Stocks that Insiders Love
20 Stocks Wall Street Analysts Love the Most20 Stocks Wall Street Analysts Love the Most
15 Technology Stocks that Analysts Love15 Technology Stocks that Analysts Love
20 "Past Their Prime" Stocks to Dump From Your Portfolio20 "Past Their Prime" Stocks to Dump From Your Portfolio
7 Best Stocks to Own Right Now7 Best Stocks to Own Right Now



Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel